Accueil > Actualité
Actualite financiere : Actualite bourse

Pfizer: rescruiting for gene therapy

( - Pfizer and Sangamo Therapeutics have announced the reopening of enrollment in the AFFINE Phase 3 trial evaluating giroctocogen fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A.

Trial sites will begin to resume enrolment this month, with dosing expected to resume in October.

All trial sites are expected to be active by the end of 2022 and results from the pivotal study are expected in the first half of 2024.

Copyright (c) 2022 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.